Prokidney (PROK) Research & Development (2021 - 2026)
Prokidney (PROK) posted quarterly Research & Development of $33.8 million for Q1 2026, up 24.13% year-over-year from $27.3 million in Q1 2025, and down 0.92% quarter-over-quarter from $34.2 million in Q4 2025.
Prokidney (PROK) Research & Development (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Research & Development for 6 consecutive years, with $33.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 24.13% year-over-year to $33.8 million; the TTM figure through Mar 2026 stood at $120.7 million (down 5.48% YoY), while the FY2025 annual figure was $114.1 million, down 10.61% from the prior year.
- Research & Development slipped to $33.8 million in Q1 2026 per PROK's latest filing, from $34.2 million in the prior quarter.
- Across five years, Research & Development topped out at $39.8 million in Q4 2024 and bottomed at $11.6 million in Q2 2022.
- Historically, Research & Development has averaged $27.3 million across 5 years, with a median of $27.2 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development soared 128.1% — and 2025, when it slipped 14.17%.
- Prokidney's Research & Development stood at $20.9 million in 2022, then gained by 7.84% to $22.5 million in 2023, then soared by 76.58% to $39.8 million in 2024, then declined by 14.14% to $34.2 million in 2025, then decreased by 0.92% to $33.8 million in 2026.
- Business Quant data shows PROK's Research & Development at $33.8 million in Q1 2026, $34.2 million in Q4 2025, and $26.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Prokidney | 679.95 Mn | 679.95 Mn | - | 36.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.10 Mn |
| Mar 31, 2026 | 33.84 Mn |
| Dec 31, 2025 | 34.16 Mn |
| Sep 30, 2025 | 26.82 Mn |
| Jun 30, 2025 | 25.88 Mn |
| Mar 31, 2025 | 27.26 Mn |
| Dec 31, 2024 | 39.78 Mn |
| Sep 30, 2024 | 31.25 Mn |
| Jun 30, 2024 | 29.40 Mn |
| Mar 31, 2024 | 27.23 Mn |
| Dec 31, 2023 | 22.53 Mn |
| Sep 30, 2023 | 32.20 Mn |
| Jun 30, 2023 | 26.36 Mn |
| Mar 31, 2023 | 25.62 Mn |
| Dec 31, 2022 | 20.89 Mn |
| Sep 30, 2022 | 21.13 Mn |
| Jun 30, 2022 | 11.56 Mn |
| Mar 31, 2022 | 28.49 Mn |
| Dec 31, 2021 | 10.69 Mn |
| Sep 30, 2021 | 14.74 Mn |